ACTU
Actuate Therapeutics Inc NASDAQ$2.95
Mkt Cap $69.9M
52w Low $1.58
13.2% of range
52w High $11.99
50d MA $2.68
200d MA $5.68
P/E (TTM)
-2.8x
EV/EBITDA
-5.2x
P/B
8.0x
Debt/Equity
0.1x
ROE
-280.5%
P/FCF
-6.7x
RSI (14)
—
ATR (14)
—
Beta
0.86
50d MA
$2.68
200d MA
$5.68
Avg Volume
118.7K
About
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cance…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.24 | -0.18 | +25.0% | 2.27 | -0.9% | -5.3% | +0.9% | +20.7% | +9.7% | +9.3% | +25.6% | — |
| Nov 13, 2025 | AMC | -0.27 | -0.25 | +7.4% | 5.88 | +0.5% | +0.5% | +0.7% | +3.7% | -0.5% | +3.6% | +16.7% | — |
| Aug 14, 2025 | AMC | -0.19 | -0.30 | -57.9% | 8.22 | -2.9% | -1.2% | +0.4% | -3.0% | -6.6% | -6.7% | -14.8% | — |
| May 15, 2025 | AMC | -0.30 | -0.32 | -6.7% | 9.76 | +0.3% | +8.1% | +5.1% | +8.6% | +12.5% | +3.5% | -14.2% | — |
| Mar 13, 2025 | AMC | -0.29 | -0.33 | -13.8% | 7.45 | -1.6% | -2.7% | -0.7% | +0.1% | -1.3% | -6.2% | +7.4% | — |
| Nov 13, 2024 | AMC | -0.55 | -0.55 | +0.0% | 8.56 | +2.0% | -0.1% | +1.4% | +4.7% | +4.0% | +0.2% | +0.7% | — |
| Sep 24, 2024 | AMC | — | -4.20 | — | 6.52 | +0.0% | -11.0% | -6.9% | -3.8% | +14.3% | +6.1% | +30.2% | — |
| Mar 31, 2024 | AMC | — | -0.54 | — | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.50 | — | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.41 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.27 | $2.38 | +4.8% | +22.5% | +11.5% | +30.8% | +25.6% | +27.8% |
| Apr 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.72 | +0.0% | +5.8% | +20.9% | +25.0% | +25.0% | +34.3% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.10 | $5.95 | -2.5% | -4.1% | -0.2% | +3.4% | +2.6% | +2.5% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.09 | $7.19 | +1.4% | -3.0% | -1.0% | -6.2% | -2.8% | -4.5% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.12 | $8.12 | +0.0% | +1.6% | -1.8% | -5.4% | -5.5% | +3.0% |
Data updated apr 24, 2026 10:44am
· Source: massive.com